{
    "clinical_study": {
        "@rank": "30156", 
        "arm_group": {
            "arm_group_label": "Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the response of 13-valent conjugate pneumococcal\n      vaccine in patients 50 years or older with end stage renal disease on dialysis.\n\n      The study will also try to determine Streptococcus pneumoniae  colonization in patients 50\n      years or older with end stage renal disease on dialysis."
        }, 
        "brief_title": "Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "End Stage Renal Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the study is to determine the immunogenicity of 13-valent conjugate\n      pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis.\n      Patients will receive one dose of 0.5ml of Prevnar-13 intra-muscularly. Antibody response to\n      pneumococcal serotypes will be studied ar 2months and 12 months after administration of\n      vaccine.\n\n      The study will try to determine Streptococcus pneumoniae  colonization in patients 50 years\n      or older with end stage renal disease on dialysis and also investigate if there are any\n      change in Streptococcus pneumoniae colonization after Prevnar-13 vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients \u2265 50years of age with End stage renal disease on dialysis (both\n             hemodialysis and peritoneal dialysis).\n\n          -  Scheduled to receive pneumococcal vaccine either after 5years of previous vaccination\n             or starting vaccination as part of standard care during the study period\n\n        Exclusion Criteria:\n\n          -  History of S. pneumoniae infection within the  last 5 years\n\n          -  Vaccinated with an influenza- or diphtheria-containing vaccine within the last 6\n             months\n\n          -  History of any severe adverse reaction associated with a vaccine\n\n          -  Received  gamma-globulins within the previous 6 months\n\n          -  Known or suspected HIV or on immunosuppressive medications.\n\n          -  Functional or anatomic asplenia\n\n          -  serious chronic medical condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974817", 
            "org_study_id": "WI170883"
        }, 
        "intervention": {
            "arm_group_label": "Vaccine", 
            "description": "0.5ml IM for one dose", 
            "intervention_name": "13-valent conjugate pneumococcal vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Prevnar-13"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pneumococcal vaccine", 
            "end stage renal disease", 
            "dialysis"
        ], 
        "lastchanged_date": "November 4, 2013", 
        "location": {
            "contact": {
                "last_name": "Mary Swails, RN", 
                "phone": "517-364-7373"
            }, 
            "facility": {
                "address": {
                    "city": "Lansing", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48195"
                }, 
                "name": "Sparrow Dialysis at Saint Lawrence Campus"
            }, 
            "investigator": {
                "last_name": "Subhashis Mitra", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis.", 
        "overall_official": {
            "affiliation": "Michigan State University", 
            "last_name": "Subhashis Mitra, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Study the immunologic response after administration of single dose 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis.", 
            "measure": "Immunogenicity of 13-valent conjugate pneumococcal vaccine in in patients 50 years or older with end stage renal disease on dialysis", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974817"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Michigan State University", 
            "investigator_full_name": "Subhashis Mitra", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Michigan State University", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Michigan State University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}